ObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantSwiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in Share XObsEva files uterine fibroid drug in US, chasing AbbVie, Myovanthttps://pharmaphorum.com/news/obseva-filed-uterine-fibroid-drug-in-us-chasing-abbvie-myovant/
FDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clashMyovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first Share XFDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clashhttps://pharmaphorum.com/news/fda-clears-myovants-relugolix-for-uterine-fibroids-setting-up-abbvie-clash/
AbbVie’s elagolix shows promise in uterine fibroids treatmentAbbVie’s elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for Share XAbbVie’s elagolix shows promise in uterine fibroids treatmenthttps://pharmaphorum.com/news/abbvies-elagloix-shows-promise-uterine-fibroids-treatment/
